SCHEMBL2577181

SCHEMBL2577181

Oc1ccccc1Cc1ccc(F)cc1

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.70
HSPA5 P11021 1/20 0.60
MPO P05164 2/20 0.57
ALOX5 P09917 2/20 0.50
BCL2 P10415 1/20 0.47
BCL2L1 Q07817 1/20 0.47
HSP90AA1 P07900 2/20 0.46
HIF1A Q16665 2/20 0.43
CYP2D6 P10635 1/20 0.43
TSHR P16473 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPT P10636 1/20 0.43
CYP3A4 P08684 1/20 0.43
HPGD P15428 1/20 0.43
ALOX15 P16050 1/20 0.43
HSD17B10 Q99714 1/20 0.43
HSP90B1 P14625 1/20 0.43
TAAR1 Q96RJ0 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9776607 0.89 KEAP1 (0.86) KEAP1HSPA5ALOX5BCL2BCL2L1
SCHEMBL30616875 0.89 KEAP1 (0.86) KEAP1HSPA5ALOX5BCL2BCL2L1
SCHEMBL5188628 0.84 HTR2A (0.46) KEAP1MPOHSP90AA1HSP90B1TAAR1
SCHEMBL29506902 0.83 KEAP1 (1.00) KEAP1HSPA5ALOX5BCL2BCL2L1
SCHEMBL8925742 0.83 KEAP1 (0.76) KEAP1HSPA5ALOX5BCL2BCL2L1
SCHEMBL68653 0.83 KEAP1 (1.00) KEAP1HSPA5ALOX5BCL2BCL2L1
SCHEMBL30335116 0.82 KEAP1 (0.75) KEAP1HSPA5MPOALOX5BCL2
SCHEMBL87816 0.82 KEAP1 (0.75) KEAP1HSPA5MPOALOX5BCL2
SCHEMBL7470790 0.82 MPO (0.65) KEAP1HSPA5MPOTAAR1
SCHEMBL920838 0.81 KEAP1 (0.96) KEAP1HSPA5ALOX5BCL2BCL2L1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590072-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2026-03-31 US disclosed
EP-4662219-A2 PRODRUGS OF THYROID HORMONE ANALOGS, METHODS OF MAKING AND METHODS OF USING THEREOF ASCLETIS PHARMA (CHINA) CO., LIMITED (HK) 2025-12-17 EP disclosed
US-20240294561-A1 Prodrugs of Thyroid Hormone Analogs, Methods of Making and Methods of Using Thereof ASCLETIS PHARMA (CHINA) CO., LIMITED (CN) 2024-09-05 US disclosed
WO-2024167961-A2 PRODRUGS OF THYROID HORMONE ANALOGS, METHODS OF MAKING AND METHODS OF USING THEREOF GANNEX, LLC (US) 2024-08-15 WO disclosed
US-20230242492-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-08-03 US disclosed
US-20230242492-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-08-03 US disclosed
US-11667606-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2023-06-06 US disclosed
US-11667606-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2023-06-06 US disclosed
US-11667606-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2023-06-06 US disclosed
EP-4167986-A1 THYROMIMETICS Autobahn Therapeutics, Inc. (US) 2023-04-26 EP disclosed
EP-1541578-A1 PROCESS FOR SELECTIVE PRODUCTION OF ARYL 5-THIO-BETA-D-ALDOHEXOPYRANOSIDES TAISHO PHARMACEUTICAL CO., LTD (JP) 2005-06-15 EP disclosed
EP-1528066-A1 ARYL 5-THIO-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME TAISHO PHARMACEUTICAL CO., LTD (JP) 2005-05-04 EP disclosed
US-20050085541-A1 Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2005-04-21 US disclosed
EP-1471049-A1 NOVEL THYROID HORMONE RECEPTOR LIGAND, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND USE THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2004-10-27 EP disclosed
EP-0540673-B1 ACETYLENE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY ABBOTT LAB (US) 1996-10-16 EP disclosed
US-5559144-A LIPOXYGENASE INHIBITORS, INHIBITORS OF BIOSYNTHESIS OF LEUKOTRIENES ABBOTT LABORATORIES (US) 1996-09-24 US disclosed
US-5476873-A Inhibit biosynthesis of leukotrienes ABBOTT LABORATORIES (US) 1995-12-19 US disclosed
EP-0540673-A4 1994-04-27 EP disclosed
EP-0540673-A1 ACETYLENE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY. ABBOTT LAB (US) 1993-05-12 EP disclosed
WO-1992001682-A1 ACETYLENE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY ABBOTT LABORATORIES (US) 1992-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240294561-A1 Prodrugs of Thyroid Hormone Analogs, Methods of Making and Methods of Using Thereof THRB, THRA, TSHR KEAP1 3878/4885HSPA5 3756/4885MPO 3989/4885
US-11667606-B2 Thyromimetics TPO, TSHR, TTR KEAP1 2106/4885HSPA5 3213/4885MPO 1959/4885
US-20050085541-A1 Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof TSHR, THRA, THRB KEAP1 4101/4885HSPA5 2007/4885MPO 4829/4885
US-20230242492-A1 THYROMIMETICS TPO, TSHR, THOP1 KEAP1 867/4885HSPA5 479/4885MPO 3097/4885
US-12590072-B2 Thyromimetics THRB, TSHR, TRHR KEAP1 1497/4885HSPA5 1691/4885MPO 3118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.